WHAT IS CLAIMED IS:

1. A composition capable of causing the appearance of IL-12 in plasma, the composition essentially consisting of:

a foreign antigen;

at least one Th1 cytokine; and

a DC maturation molecule.

2. The composition of claim 1 where the foreign antigen is an alloantigen.

3. The composition of claim 1 where the Th1 cytokine is one or more of the following: IL-1, IL-2, IL-6, IL-8, IL-15, Interferon-gamma, TNF-alpha, GM-CSF.

4. The composition of claim 1 where the DC maturation molecule is CD40L and/or FasL.

5. The composition of claim 2 where the alloantigen is on a living T-cell.

6. The composition of claim 5 where the T-cells are CD4+ cells or Th1 cells.

7. The composition of claim 6 where the Th1 cell is activated.

8. The composition of claim 7 where the Th1 cells are activated by cross-linking CD3 and CD28.

9. The composition of claim 8 where the activated Th1 cells secrete one or more of the following Th1 cytokines: IL-2, IFN-gamma and GM-CSF.

10. The composition of claim 9 where the activated Th1 cells express the DC maturation molecule CD40L and/or FasL on their surface.

11. The composition of claim 1 where the components are immobilized on a surface.

12. The composition of claim 11 where the surface is biodegradable.

13. The composition of claim 5 where the living T-cells are packaged in a syringe or flexible container.

14. The composition of claim 13 where the cells are at a concentration of 1 x 10^7 cells/ml or greater.

15. The composition of claim 14 where the cells are suspended in a non-nutrient media.

16. ~~A method of increasing plasma levels of IL-12 in a patient comprising:~~

~~administering~~ Use of a composition comprising of allogeneic cells wherein at least a portion of the cells are activated T-cells in the manufacture of a medicament for increasing plasma levels of IL-12 in a patient; ~~monitoring the level of IL-12 in the patient; and~~

wherein the composition is to be administered to the patient; wherein the levels of IL-12 is to be monitored and ~~readministering~~wherein the composition is to be re-administered if sufficient levels of IL-12 are not detected in the plasma of the patient.

17. The use~~method~~ of claim 16 wherein the detection of IL-12 is not toxic to the patient.

18. The use~~method~~ of claim 16 wherein the activated T-cells are CD4+ cells.

19. The use~~method~~ of claim 18 wherein the activated CD4 cells are Th1 cells.

20. The use~~method~~ of claim 19 wherein the Th1 cells are activated by cross-linking CD3 and CD28.

21. The use~~method~~ of claim 16 wherein administration of the composition increases the level of IFN-gamma in the patient and/or the Th1 response.

22. The use~~method~~ of claim 16 wherein the level of IL-12 in the plasma of the patient is at least about 5000pg/ml.

23. ~~A method of treating a patient with a disease comprising: administering~~ Use of a composition comprising allogeneic cells wherein at least a portion are activated T-cells in the manufacture of a medicament for treating a disease in a patient, wherein the T-cells are activated by cross-linking one or more agents bound to the cell surface moieties on the T-cells; wherein the composition is to be administered to the patient; wherein the levels of IL-12 in the patient's plasma is to be monitored; and ~~monitoring the level of IL-12 in the patient's plasma; and~~ wherein ~~readministering~~ the composition is to be re-administered if IL-12 is not detected in the plasma of the patient.

24. The use~~method~~ of claim 23 wherein the disease is cancer or is a result of a pathogenic infection.

25. The use~~method~~ of claim 23 wherein the readministration~~ering~~ is to be repeated until the concentration of the endogenous IL-12 is detectable.

26. A therapeutic composition for increasing the endogenous levels of IL-12 comprising activated allogeneic T cells wherein administration of the composition leads to detectable levels of endogenous IL-12 in the plasma of a patient without toxicity to the patient.

27. The composition of claim 26 wherein the patient has cancer or an infectious disease.

28. The composition of claim 26 wherein the T-cells are CD4+ cells.

29. The composition of claim 26 wherein the T-cells are activated by cross-linking one or more agents that are bound to the cell surface moieties on the T-cells.

30. The composition of claim 26 wherein the one or more agents are monoclonal antibodies such as anti-CD3 and anti-CD28 monoclonal antibodies.